Summary
CSF levels of proteins related to the lesions of Alzheimer’s Disease (AD) may be informative. These include the microtubule-associated protein tau, an integral component of neurofibrillary tangles, and Aβ, a 4kDa protein that accumulates in senile plaque amyloid. Many studies have found that CSF tau is increased in AD compared to normal controls (NC). CSF tau may be increased in a minority of patients with destructive neurological disorders or several neurodegenerative conditions, making its use in differential diagnosis less clear. CSF tau consists of fragments that lack extensive phosphorylation. CSF levels of Aβ species ending at residue 40 are unchanged in AD. However species ending at residue 42 (Aβ42) are significantly decreased in AD compared to NC. Decreased Aβ42 may be found in patients with other dementias, some of whom may harbor AD pathology. Simultaneous measurement of CSF Aβ42 and tau may improve discrimination between AD and NC, and may facilitate the diagnosis of early stage AD.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arai H, Terajima M, Miura M, Higuchi S, Muramatsu T, Machida N, Seiki H, Takase S, Clark CM, Lee VM-Y, Trojanowski JQ, Sasaki A (1995) Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer’s disease. Ann Neurol 38: 649–652
Blennow K, Wallin A, Agren H, Spenger C, Siegfried J, Vanmechelen E (1995) Tau protein in cerebrospinal fluid. A biochemical marker for axonal degeneration in Alzheimer disease? Molec Chem Neuropathol 26: 231–245
Brioni A, Decker M (1997) Pharmacological treatment of Alzheimer’s disease: molecular and neurobiological foundations, Wiley-Liss, New York, pp 345–366
Cummings BJ, Cottman CW (1995) Image analysis of β-amyloid load in Alzheimer’s disease and relation to dementia severity. Lancet 346: 1524–1528
Dickson DW (1997) The pathogenesis of senile plaques. J Neuropathol Exp Neurol 56: 321–339
Feany D, Dickson D (1996) Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann Neurol 40: 139–148
Galasko D, Hansen LA, Katzman R, Wiederholt W, Masliah E, Terry R, Hill LR, Lessin P, Thal LJ (1994) Clinical-neuropathological correlations in Alzheimer’s disease and related dementias. Arch Neurol 51: 888–895
Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, Seubert P (1997) Assessment of cerebrospinal fluid levels of tau in mildly demented patients with Alzheimer’s disease. Neurology 48: 632–635
Goedert M (1993) Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci 16: 460–465, 1993
Goedert M, Spillantini MG, Cairns NJ, Crowther RA (1992) Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 8: 159–168
Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA (1996) Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383: 550–553
Hardy J (1997) Amyloid, the presenilins, and Alzheimer’s disease. Trends Neurosci 20: 154–159
Ida N, Hartman T, Pantel T, Schroder J, Zerfass R, Forstl H, Sandbrink R, Masters CL, Beyreuther K (1996) Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid by a newly developed sensitive Western blot assay. J Biol Chem 271: 22908–22914
Isoe K, Urakami K, Shimomura T, Wakutani Y, Ji Y, Adachi Y, Takahashi K (1996) Tau proteins in cerebrospinal fluid from patients with Alzheimer’s disease: a longitudinal study. Dementia 7: 175–176
Jellinger K, Danielczyk W, Fischer P, Gabriel E (1990) Clinicopathological analysis of dementia disorders in the elderly. J Neurol Sci 95: 239–258
Jensen M, Basun H, Lannfelt L (1995) Increased cerebrospinal fluid tau in patients with Alzheimer’s disease. Neurosci Lett 186: 189–191
Johnson GV, Seubert P, Cox TM, Motter R, Brown JP, Galasko D (1997) The tau protein in human cerebrospinal fluid is Alzheimer’s disease consists of proteolytically derived fragments. J Neurochem 68: 430–433
Kanai M, Matsubara E, Igeta Y, Tomidokoro K, Ishiguro T, Kawarabayashi T, Watanabe M, Shizuka M, Nakamura T, Okamoto K, Hirai S, Shoji M (1996) Cerebrospinal fluid tau and beta-amyloid 1–40/42 in Alzheimer’s disease. Soc Neurosci Abstr 22: 1169
Klatka LA, Schiffer RB, Powers JM, Kazee AM (1996) Incorrect diagnosis of Alzheimer’s disease. A clinicopathologic study. Arch Neurol 53: 35–42
McKhann G, Drachman D, Folstein MF, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34: 939–944
Mori H, Hosoda K, Matsubara E, Nakamoto T, Furiya Y, Endoh R, Usami M, Shoji M, Maruyama S, Hirai S (1995) Tau in cerebrospinal fluids: establishment of the sandwich ELISA with antibody specific to the repeat sequence in tau. Neurosci Lett 186: 181–183
Motter R, Vigo-Pelfrey C, Kholodenko D, Barbour R, Johnson-Wood K, Galasko D, Chang L, Miller B, Clark C, Gren R, Olson D, Southwick P, Wolfert R, Munroe B, Lieberburg I, Seubert P, Schenk D (1995) Reduction of β-Amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 38: 643–648
Nakamura T, Shoji M, Harigaya Y, Watanabe M, Hosoda K, Cheung TT, Shaffer LM, Golde TE, Younkin LH, Younkin SG, Hirai S (1994) Amyloid β protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer’s disease. Ann Neurol 36: 903–911
Otto M, Wiltfang J, Tumani H, Zerr I, Lautsch M, Kornhuber J, Weber T, Kretschmer HA, Poser S (1997) Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci Lett 225: 210–212
Riemenschneider NM, Buch K, Schmolke M, Kurz A, Guder WG (1996) Cerebrospinal fluid tau is elevated in early Alzheimer’s disease. Neurosci Lett 212: 209–211
Rösier N, Wichart I, Jellinger KA (1996) Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 60: 237–238
Saunders AM, Strittmatter WJ, Schmechel D, et al (1993) Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 43: 1467–1472
Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nature Med 2: 864–870
Selkoe DJ (1994) Alzheimer’s disease: a central role for amyloid. J Neuropathol Exp Neurol 53: 438–447
Selkoe DJ (1996) Amyloid β-protein and the genetics of Alzheimer’s disease. J Biol Chem 271: 18295–18298
Seubert P, Motter R, Schenk D, Lieberburg I, Kholodenko D, Galasko D, Thomas R, Chang L, Miller B, Clark C, Knopman D, Kaye J, Green RC, Kertiles M, Bashirzadeh R, Boss M (1998) APOE genotype influences the CSF level of Aβ42 in Alzheimer’s disease (in preparation)
Strittmatter WJ, Roses AD (1995) Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci (USA) 92: 4725–4727
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses (1993) Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90: 980–984
Tamaoka A, Sawamura N, Fukushima T, Shoji S, Matsubara E, Shoji M, Hirai S, Furiya Y, Endoh H, Mori H (1997) Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer’s disease. J Neurol Sci 148: 4–45
Trojanowski JQ, Lee VM-Y (1994) Phosphorylation of neuronal cytoskeletal proteins in Alzheimer’s disease and Lewy body dementias. Ann NY Acad Sci 747: 92–109
Van Gool WA, Bolhuis PA (1991) Cerebrospinal fluid markers of Alzheimer’s disease. JAGS 39: 1025–1039
Van Gool WA, Kuiper MA, Walstra GJM, Wolters E Ch, Bolhuis PA (1995) Concentrations of amyloid β protein in cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 37: 277–279
Vandermeeren M, Mercken M, Vanmechelen E, Six J, Van de Voorde A, Martin J-J, Cras P (1993) Detection of tau proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 61: 1828–1834
Vigo-Pelfrey C, Le D, Keim P, Lieberburg I, Schenk DB (1993) Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem 61: 1965–1968
Vigo-Pelfrey C, Seubert P, Barbour R, Blomquist C, Lee M, Lee D, Coria F, Chang L, Miller B, Lieberburg I, Schenk D (1995) Elevation of micro-tubule-associated protein tau in the cerebrospinal fluid of Alzheimer’s patients. Neurology 45: 788–793
Wolozin B, Davies P (1987) Alzheimer-related neuronal protein A68: specificity and distribution. Ann Neurol 22: 521–526, 1987
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Wien
About this paper
Cite this paper
Galasko, D. (1998). Cerebrospinal fluid levels of Aβ42 and tau: potential markers of Alzheimer’s disease. In: Jellinger, K., Fazekas, F., Windisch, M. (eds) Ageing and Dementia. Journal of Neural Transmission. Supplementa, vol 53. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6467-9_19
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6467-9_19
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-83114-4
Online ISBN: 978-3-7091-6467-9
eBook Packages: Springer Book Archive